Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 12/2009

01-12-2009 | Article

Diagnostic value of procalcitonin in acutely hospitalized elderly patients

Authors: O. Steichen, E. Bouvard, G. Grateau, S. Bailleul, J. Capeau, G. Lefèvre

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 12/2009

Login to get access

Abstract

The aim of this study was to evaluate procalcitonin as an adjunct to diagnose bacterial infections in older patients. One hundred seventy-two patients admitted to an acute-care geriatric unit during a 6-month period were prospectively included, 39 of them with an invasive bacterial infection. The best cut-off value to rule in a bacterial infection was 0.51 µg/l with sensitivity 64% and specificity 94%. The best cut-off value to rule out a bacterial infection was 0.08 µg/l with sensitivity 97% and specificity 20%. Procalcitonin was inconclusive (between 0.08 and 0.51 µg/l) for 112 admissions. Procalcitonin over 0.51 µg/l was useless 22 times out of 33 (infection already ruled in on clinical grounds) and misleading in eight of the 11 remaining cases (no infection). Procalcitonin below 0.08 µg/l was useless 23 times out of 27 (infection already ruled out on clinical grounds) and misleading in one of the four remaining cases (infection). Despite a good overall diagnostic accuracy, the clinical usefulness of PCT to diagnose invasive bacterial infections in elderly patients hospitalized in an acute geriatric ward appears to be very limited.
Literature
1.
go back to reference Stucker F, Herrmann F, Graf JD, Michel JP, Krause KH, Gavazzi G (2005) Procalcitonin and infection in elderly patients. J Am Geriatr Soc 53:1392–1395CrossRefPubMed Stucker F, Herrmann F, Graf JD, Michel JP, Krause KH, Gavazzi G (2005) Procalcitonin and infection in elderly patients. J Am Geriatr Soc 53:1392–1395CrossRefPubMed
2.
go back to reference Briel M, Schuetz P, Mueller B, Schild U, Nusbaumer C, Périat P, Bucher HC, Christ-Crain M (2008) Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med 168:2000–2007CrossRefPubMed Briel M, Schuetz P, Mueller B, Schild U, Nusbaumer C, Périat P, Bucher HC, Christ-Crain M (2008) Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med 168:2000–2007CrossRefPubMed
3.
go back to reference Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47:1245–1251CrossRefPubMed Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47:1245–1251CrossRefPubMed
4.
go back to reference Hubl W, Krassler J, Zingler C, Pertschy A, Hentschel J, Gerhards-Reich C, Mack M, Demant T (2003) Evaluation of a fully automated procalcitonin chemiluminescence immunoassay. Clin Lab 49:319–327PubMed Hubl W, Krassler J, Zingler C, Pertschy A, Hentschel J, Gerhards-Reich C, Mack M, Demant T (2003) Evaluation of a fully automated procalcitonin chemiluminescence immunoassay. Clin Lab 49:319–327PubMed
5.
go back to reference The ACCP/SCCM American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864–874CrossRef The ACCP/SCCM American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864–874CrossRef
6.
go back to reference Coste J, Pouchot J (2003) A grey zone for quantitative diagnostic and screening tests. Int J Epidemiol 32:304–313CrossRefPubMed Coste J, Pouchot J (2003) A grey zone for quantitative diagnostic and screening tests. Int J Epidemiol 32:304–313CrossRefPubMed
7.
go back to reference Hanley JA, McNeil BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29–36PubMed Hanley JA, McNeil BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29–36PubMed
8.
go back to reference Hanley JA, McNeil BJ (1983) A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148:839–843PubMed Hanley JA, McNeil BJ (1983) A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148:839–843PubMed
9.
go back to reference Christ-Crain M, Müller B (2006) Procalcitonin: you only find what you look for, and you only look for what you know. J Am Geriatr Soc 54:546CrossRefPubMed Christ-Crain M, Müller B (2006) Procalcitonin: you only find what you look for, and you only look for what you know. J Am Geriatr Soc 54:546CrossRefPubMed
10.
go back to reference Mitaka C (2005) Clinical laboratory differentiation of infectious versus non-infectious systemic inflammatory response syndrome. Clin Chim Acta 351:17–29CrossRefPubMed Mitaka C (2005) Clinical laboratory differentiation of infectious versus non-infectious systemic inflammatory response syndrome. Clin Chim Acta 351:17–29CrossRefPubMed
11.
go back to reference Rothenburger M, Markewitz A, Lenz T, Kaulbach HG, Marohl K, Kuhlmann WD, Weinhold C (1999) Detection of acute phase response and infection. The role of procalcitonin and C-reactive protein. Clin Chem Lab Med 37:275–279CrossRefPubMed Rothenburger M, Markewitz A, Lenz T, Kaulbach HG, Marohl K, Kuhlmann WD, Weinhold C (1999) Detection of acute phase response and infection. The role of procalcitonin and C-reactive protein. Clin Chem Lab Med 37:275–279CrossRefPubMed
12.
go back to reference Giamarellos-Bourboulis EJ, Mega A, Grecka P, Scarpa N, Koratzanis G, Thomopoulos G, Giamarellou H (2002) Procalcitonin: a marker to clearly differentiate systemic inflammatory response syndrome and sepsis in the critically ill patient? Intensive Care Med 28:1351–1356CrossRefPubMed Giamarellos-Bourboulis EJ, Mega A, Grecka P, Scarpa N, Koratzanis G, Thomopoulos G, Giamarellou H (2002) Procalcitonin: a marker to clearly differentiate systemic inflammatory response syndrome and sepsis in the critically ill patient? Intensive Care Med 28:1351–1356CrossRefPubMed
13.
go back to reference Steinbach G, Rau B, Debard AL, Javourez JF, Bienvenu J, Ponzio A, Bonfà A, Hubl W, Demant T, Külpmann WR, Buchholz J, Schumann G (2004) Multicenter evaluation of a new immunoassay for procalcitonin measurement on the Kryptor System. Clin Chem Lab Med 42:440–449CrossRefPubMed Steinbach G, Rau B, Debard AL, Javourez JF, Bienvenu J, Ponzio A, Bonfà A, Hubl W, Demant T, Külpmann WR, Buchholz J, Schumann G (2004) Multicenter evaluation of a new immunoassay for procalcitonin measurement on the Kryptor System. Clin Chem Lab Med 42:440–449CrossRefPubMed
14.
go back to reference Dwolatzky T, Olshtain-Pops K, Yinnon AM, Raveh D, Rogowski O, Shapira I, Rotstein R, Berliner S, Rudensky B (2005) Procalcitonin in the elderly: normal plasma concentrations and response to bacterial infections. Eur J Clin Microbiol Infect Dis 24:763–765CrossRefPubMed Dwolatzky T, Olshtain-Pops K, Yinnon AM, Raveh D, Rogowski O, Shapira I, Rotstein R, Berliner S, Rudensky B (2005) Procalcitonin in the elderly: normal plasma concentrations and response to bacterial infections. Eur J Clin Microbiol Infect Dis 24:763–765CrossRefPubMed
15.
go back to reference Caterino JM, Scheatzle MD, Forbes ML, D'Antonio JA (2004) Bacteremic elder emergency department patients: procalcitonin and white count. Acad Emerg Med 11:393–396PubMed Caterino JM, Scheatzle MD, Forbes ML, D'Antonio JA (2004) Bacteremic elder emergency department patients: procalcitonin and white count. Acad Emerg Med 11:393–396PubMed
16.
go back to reference Delèvaux I, André M, Colombier M, Albuisson E, Meylheuc F, Bègue RJ, Piette JC, Aumaître O (2003) Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes? Ann Rheum Dis 62:337–340CrossRefPubMed Delèvaux I, André M, Colombier M, Albuisson E, Meylheuc F, Bègue RJ, Piette JC, Aumaître O (2003) Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes? Ann Rheum Dis 62:337–340CrossRefPubMed
17.
go back to reference Muñoz P, Simarro N, Rivera M, Alonso R, Alcalá L, Bouza E (2004) Evaluation of procalcitonin as a marker of infection in a nonselected sample of febrile hospitalized patients. Diagn Microbiol Infect Dis 49:237–241CrossRefPubMed Muñoz P, Simarro N, Rivera M, Alonso R, Alcalá L, Bouza E (2004) Evaluation of procalcitonin as a marker of infection in a nonselected sample of febrile hospitalized patients. Diagn Microbiol Infect Dis 49:237–241CrossRefPubMed
Metadata
Title
Diagnostic value of procalcitonin in acutely hospitalized elderly patients
Authors
O. Steichen
E. Bouvard
G. Grateau
S. Bailleul
J. Capeau
G. Lefèvre
Publication date
01-12-2009
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 12/2009
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-009-0807-4

Other articles of this Issue 12/2009

European Journal of Clinical Microbiology & Infectious Diseases 12/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine